Efficacy and safety of Enterprise stenting in the treatment of symptomatic middle cerebral artery atherosclerotic stenosis
10.3760/cma.j.issn.1673-4165.2024.07.001
- VernacularTitle:Enterprise支架置入术治疗有症状大脑中动脉粥样硬化狭窄的有效性和安全性
- Author:
He ZHANG
1
;
Li MA
;
Guangxin DUAN
;
Xi ZHANG
;
Tingzheng ZHANG
;
Yun LUO
;
Yun XU
;
Jingwei LI
Author Information
1. 南京大学医学院附属鼓楼医院神经内科，南京 210008
- Keywords:
Intracranial arteriosclerosis;
Middle cerebral artery;
Ischemic stroke;
Ischemic attack, transient;
Endovascular procedures;
Stents;
Treatment outcome;
Recur
- From:
International Journal of Cerebrovascular Diseases
2024;32(7):481-486
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of Enterprise stenting in the treatment of symptomatic middle cerebral artery atherosclerotic stenosis.Methods:Patients with symptomatic middle cerebral artery atherosclerotic stenosis underwent Enterprise stenting in the Department of Neurology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School from January 2020 to December 2022 were retrospectively included. The degree of residual stenosis, periprocedural complications, in-stent restenosis and stroke recurrence during follow-up were evaluated.Results:A total of 75 patients were enrolled, including 55 males (73.3%), aged 58±9.7 years. The last preprocedural symptom was stroke in 65 cases (86.7%) and transient ischemic attack in 10 cases (13.3%). Sixty-seven patients (89.3%) had the M1 segment stenosis of the middle cerebral artery, and 8 (10.7%) had the M2 segment stenosis. The degree of stenosis was 88.4%±8.90%. The median time from the last onset to stenting was 18 days (interquartile range, 13-24 days). The procedural success rate was 100%, and the residual stenosis degree was 17.3%±6.1%. Four patients (5.3%) experienced periprocedural complications, including three ischemic strokes and one symptomatic intracranial hemorrhage. Sixty-one patients (81.3%) completed 3- to 12-month follow-up, of which 7 patients (11.5%) had in-stent restenosis and 2 (3.3%) had recurrent ischemic stroke.Conclusion:Enterprise stenting may be safe and effective in the treatment of symptomatic middle cerebral artery stenosis.
